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PQUARTERLY FOCUS ISSUE: HEART FAILURE
Glucose, Obesity, Metabolic Syndrome, and Diabetes
Relevance to Incidence of Heart Failure
Tamara B. Horwich, MD, MS, Gregg C. Fonarow, MD
Los Angeles, California
Heart failure (HF) is common, results in poor clinical outcomes, and is associated with large health care costs.
The incidence of HF continues to rise, with approximately 670,000 new cases per year and a 20% lifetime risk
of HF for persons 40 years and older in the U.S. Risk factors for HF have been identified, and thus preventative
strategies should have a positive effect on disease burden, morbidity, and mortality. Although coronary artery
disease and hypertension have traditionally been considered among the most important modifiable risk factors
for the development of HF, recent studies have highlighted the importance of increasingly prevalent metabolic
risk factors: glucose, diabetes, obesity, and the metabolic syndrome. This report will present evidence for the
link between glucose, diabetes, obesity, metabolic syndrome, and incident HF. Furthermore, we will discuss how
risk factor modification and other preventive therapies may help curb the rising incidence of HF. (J Am Coll
Cardiol 2010;55:283–93) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.029t
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reart failure (HF) continues to be a major public health
oncern, as HF incidence, hospitalizations, and cost con-
inue to rise. There are approximately 670,000 new cases of
F per year in the U.S. in persons over age 45 years.
ncidence of HF increases in older age, with an incidence
ate (per 1,000 person-years) of 9.2 and 4.7 for men and
omen age 65 to 74 years, 22.3 and 14.8 for men and
omen age 75 to 84 years, and 41.9 and 32.7 for men
nd women age 85 years and older, respectively (1). Life-
ime risk of developing HF is approximately 20% for
ersons at age 40 years, and remains at 20% for persons
eaching 80 years of age. HF hospitalizations have tripled in
he time period between 1979 and 2004, due in part to the
ging population and advanced cardiovascular therapeutics
hat prolong survival (2–4). Age-adjusted hospitalization
ates for primary diagnoses of HF increased from 1979 to
004, from 219 to 390 per 100,000, respectively (Fig. 1) (3).
he estimated cost burden of HF in the U.S. in 2009 is
37.2 billion (1).
isk Factors for Incident HF: Initial Studies
here are numerous established and hypothesized risk
actors for the development of HF (Table 1). Large epide-
iologic studies have helped delineate risk factors for HF in
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ccepted July 8, 2009.he general population. A study of a 1970 Framingham
ohort followed for 20 years found that hypertension had
he greatest population-attributable risk for HF, accounting
or 39% of HF cases in men and 59% in women. History of
yocardial infarction had the second highest population-
ttributable risk: 34% of HF cases in men and 13% in
omen. Other risk factors for HF included diabetes, left
entricular hypertrophy, and valvular heart disease (5).
nother large prospective cohort study, the NHANES I
First National Health and Nutrition Examination Survey
pidemiologic Follow-up Study), also initiated in the
970s, found that coronary artery disease was the largest
ndependent risk factor for HF, in addition to hypertension,
moking, physical inactivity, overweight status, low educa-
ional level, diabetes, and valvular heart disease (6). Since
iabetes, obesity, and the metabolic syndrome have become
ncreasingly prevalent in the U.S. population over the past
ecades since the inception of the above studies (1) (Fig. 1),
he impact of these risk factors on the growing epidemic of
F warrants additional attention.
iabetes, Glucose, and Incident HF
he prevalence of diabetes in the U.S., the vast majority of
hich is type 2 diabetes, has increased by more than 60%
ince 1990. Diabetes is now diagnosed in approximately
0% of those 20 years of age and 15% of those 65 years
f age; furthermore, undiagnosed diabetes is present in an
dditional approximate 7% and 3% of these age groups,
espectively (1). The total prevalence of diabetes is expected
o more than double by 2050 (1).
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Metabolic Factors and Incident HF January 26, 2010:283–93The Framingham study ini-
tially established that a clinical
history of diabetes was indepen-
dently associated with risk of de-
veloping HF, with a 2-fold in-
creased risk in men and a 5-fold
increased risk in women (7).
More recent studies (8,9) have
reported higher annual inci-
dences of HF in diabetic pa-
ients, however; for example, 31 per 1,000 person-years were
eported in a cohort study using a Kaiser Permanente
orthwest database (9), compared with 9 to 14 cases per
,000 reported in Framingham (7). Although diabetes
redicts the risk of developing HF independent of age,
ender, or race/ethnicity, it confers a relatively higher
elative risk of HF in populations of women and young
eople (9,10). For example, among 2,391 women with
oronary artery disease, but no HF, at baseline followed
n the HERS (Heart and Estrogen/progestin Replace-
ent Study), diabetes was the strongest independent risk
actor for development of HF, with an adjusted hazard
atio of 3.1 (95% confidence interval [CI]: 2.3 to 4.2) (10).
In patients with diabetes, the degree of glycemic control
s indexed by glycosylated hemoglobin (HbA1c) is associ-
ted with the magnitude of HF risk (11–13). In a cohort
tudy of 48,858 adult patients with (predominantly type 2)
iabetes, each 1% increase in HbA1c was associated with an
% increased risk of HF hospitalization or HF death, even
fter adjusting for demographics, medical history, medica-
ions, and other risk factors (11). Among 1,827 participants
n the ARIC (Atherosclerosis Risk in Communities) study
ith diabetes and no evidence of HF at baseline, risk of HF
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
HbA1c  glycosylated
hemoglobin
HF  heart failure
TZD  thiazolidinedione
Figure 1 Age-Adjusted Hospitalization Rates for HF
National Hospital Discharge Survey, 1979 to 2004 (left). Trends of age-adjusted h
heart failure as the first-listed or additional (2nd to 7th) diagnosis for men and wo
in the U.S. over the past decades (right). Reprinted with permission from Lloyd-Joncreased proportionally with HbA1c; even in those without
oronary disease, HbA1c of 6.1% to 7%, 7.1% to 8%, and
8% (compared with HbA1c6%) corresponded to relative
isks of developing HF of 1.7, 2.5, and 3.1, respectively.
Not only HbA1c, but also elevated glucose level, is a risk
actor for HF, independent of the presence of diagnosed or
reated diabetes. In a prospective cohort study of 31,546
ubjects at high risk of cardiovascular disease, fasting plasma
lucose was an independent predictor of hospitalization for
F; per mmol increase in fasting plasma glucose, relative
isk was 1.23 (95% CI: 1.03 to 1.47) in subjects without
iabetes and 1.04 (95% CI: 1.01 to 1.07) for those with
iabetes (14). Impaired fasting glucose and/or impaired
lucose tolerance were also linked to the incidence of HF in
nondiabetic population of over 20,000 subjects living in
he Portland, Oregon, area (15).
Not surprisingly, insulin resistance without overt diabetes
s also significantly linked to the development of HF. In the
ppsala Longitudinal Study of Adult Men, in men older
han 70 years, insulin resistance and insulin sensitivity, as
easured by pro-insulin levels and euglycemic insulin clamp
esting, respectively, were independently associated with
educed risk of HF; relative risk per 1 standard deviation
ncrease in pro-insulin level was 1.29 (95% CI: 1.02 to
.64), and relative risk per 1 standard deviation decrease in
lamp glucose disposal rate relative risk was 0.66 (95% CI:
.51 to 0.86) (16). Furthermore, in men at age 50 years,
nsulin resistance and pro-insulin levels were shown to be
redictive of both left ventricular systolic and diastolic
ysfunction 20 years later, at age 70 years (17,18).
There are numerous potential pathophysiologic mecha-
isms underlying the relationship between diabetes, glucose,
nsulin resistance, and HF, in addition to the well-known
ailure hospitalization rate (per 100,000) from 1979 to 2004 among patients with
eprinted with permission from Fang et al. (3). Trends in prevalence of diabetes
al. (1).eart f
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January 26, 2010:283–93 Metabolic Factors and Incident HFiabetes-associated risk of coronary atherosclerosis (Fig. 2).
he heart, which requires enormous energy for daily func-
ion (5 kg ATP/day), may become less energy efficient in the
etting of insulin resistance, with decreased glucose utiliza-
ion and increased free fatty acid utilization. This metabolic
ysregulation may increase susceptibility to injury, such as
ressure overload or ischemia, and thus promote deleterious
enin-angiotensin-aldosterone system activation. Experi-
ental data link both hyperglycemia and hyperinsulinemia
ith increased sympathetic nervous system activation, a key
athophysiologic mechanism in HF. Morphologic changes
n diabetic myocardium include myocyte hypertrophy,
erivascular fibrosis, and increased collagen deposition;
hese histologic changes are likely a function of accumula-
ion of advanced glycation end products in the myocardium,
ncreased fatty acid deposition, and oxidative stress related
o hyperglycemia and hyperinsulinemia. Endomyocardial
iopsy specimens from nonischemic systolic HF patients
ave shown increased deposition of advanced glycation end
roducts and increased myocardial collagen volume fraction
n diabetic versus nondiabetic patients; both advanced gly-
stablished and Hypothesized Risk Factors for HFTable 1 Established and Hypothesized Risk Factors for HF
Major clinical risk factors
Age, male sex
Hypertension, LVH
Myocardial infarction
Diabetes mellitus
Valvular heart disease
Obesity
Minor clinical risk factors
Smoking
Dyslipidemia
Sleep-disordered breathing
Chronic kidney disease
Albuminuria
Homocysteine
Immune activation, IGF-1, TNF-alpha, IL-6, CRP
Natriuretic peptides
Anemia
Dietary risk factors
Increased HR
Sedentary lifestyle
Low socioeconomic status
Psychological stress
Toxic risk precipitants
Chemotherapy (anthracyclines, cyclophosphamide, 5-FU, trastuzumab)
Cocaine, NSAIDs
Thiazolidinediones
Doxazosin
Alcohol
Genetic risk predictors
SNP (e.g., alpha-2CDel322-325, beta-1Arg389)
Morphological risk predictors
Increased LVID, mass
Asymptomatic LV dysfunction
LV diastolic dysfunction
eprinted with permission from Schocken et al. (4).
5-FU  5-fluorouracil; CRP  C-reactive protein; HF  heart failure; HR  heart rate; IGF 
nsulinlike growth factor; IL interleukin; LVH left ventricular hypertrophy; LVID left ventricular
nternal dimension; NSAID  nonsteroidal anti-inflammatory drug; SNP  single-nucleotide
olymorphism; TNF  tumor necrosis factor.ation end products and collagen volume were associated mith higher diastolic left ventricular stiffness (19). Further-
ore, the increased intramyocardial triglyceride content in
atients with both impaired glucose tolerance and diabetes,
ay lead to lipotoxicity and cardiomyocyte apoptosis, ulti-
ately leading to cardiac dysfunction (20–26).
besity and Incident HF
trongly correlated to insulin resistance, obesity is another
merging risk factor for HF. Although the concept of a
ardiomyopathy relating to obesity had previously been
escribed (27), the strong independent and incremental
elationship between body mass index (BMI, kg/m2) and
F incidence was recently established. In a study of 5,881
articipants in the Framingham Heart Study, increase in the
isk of HF per unit BMI increase was 5% for men and 7%
or women, even after adjustment for demographics and
nown risk factors of myocardial infarction, diabetes, hy-
ertension, and cholesterol (28). The positive correlation
etween BMI and risk of HF was confirmed in a larger
rospective cohort study of 21,094 men (mean age 53 years)
ithout known coronary heart disease enrolled in the
hysicians’ Health Study (29); in this study, both over-
eight (BMI 25.0 to 29.9 kg/m2) and obesity (BMI 30
g/m2) were independently associated with risk of new-
nset HF, with adjusted relative risks compared with lean
BMI 25 kg/m2) men of 1.49 (95% CI: 1.32 to 1.69) and
.80 (95% CI: 2.24 to 3.50), respectively (Fig. 3) (29). In
ddition to BMI, level of physical activity was also associ-
ted with HF risk, with the highest relative risk of HF seen
n obese men who were also physically inactive (3.9 [95%
I: 2.6 to 6.0]) compared with men who were lean and
hysically active. Obese, active men (2.7 [95% CI: 2.1 to
.5]), overweight, inactive men (1.8 [95% CI: 1.4 to 2.2]),
s well as overweight and active men (1.5 [95% CI: 1.3 to
.7]) were all at higher risk compared with lean, active men
29). In addition to BMI, other anthropometric indices of
besity, including waist circumference and waist-to-hip
atio, have also been associated with incident HF (30).
Although the relationship between overweight/obesity
nd incident HF may be related to hemodynamic and
natomic cardiac changes related to excess body mass
31), recent evidence suggests that the relationship is also
ediated by obesity-related metabolic, inflammatory,
nd hormonal changes. Obesity is highly correlated with
nsulin resistance, which may in part potentiate the link
etween obesity and HF. In the Uppsala study, insulin
ensitivity (clamp glucose disposal rate), but not anthro-
ometric indices of obesity, was independently predictive
f HF risk when the 2 were entered together in a fully
djusted model (16). Analyses from the MESA (Multi-
thnic Study of Atherosclerosis) suggest that inflamma-
ion may potentiate the link between obesity and risk of
eveloping HF. Although risk of HF was 83% higher
n obese compared with nonobese subjects after adjust-
ent for traditional risk factors, the relationship between
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Metabolic Factors and Incident HF January 26, 2010:283–93besity and incident HF was no longer significant after
djustment for the inflammatory biomarkers interleukin-6
r C-reactive protein, which are known to be associated
ith risk of HF (32,33). Most recently, the adipokine
esistin, expressed by adipocytes and associated with insulin
esistance and inflammation, was associated with risk of
eveloping HF independent of coronary heart disease and
ther risk factors in a Framingham offspring analysis, providing
n additional clue to mechanisms underlying obesity and the
evelopment of HF (34). Other adipokines associated with
besity, including leptin and adiponectin, have not been found
Figure 2 Multiple Pathogenetic Mechanisms Involved in the Re
Figure illustration by Rob Flewell. CRP  C-reactive protein; Epi  epinephrine;
IL  interleukin; LV  left ventricular; NE  norepinephrine; RAAS  renal-angioteo independently predict new-onset HF (34,35). she Metabolic Syndrome and Incident HF
he metabolic syndrome, a cluster of risk factors for
ardiovascular disease and type 2 diabetes, is exceedingly
revalent in the U.S., with an estimated prevalence of over
5 million in those 20 years of age. The presence of
etabolic syndrome is associated with risk of cardiovascular
isease, although whether its prognostic value is equal to or
etter than the Framingham risk score, is subject to debate (1).
Since obesity, insulin resistance, and high blood pressure
re components of the metabolic syndrome, it is not
nship Between Diabetes, Metabolic Disease, and HF
ldosterone system.latio
nsin-aurprising that the metabolic syndrome has been linked to
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January 26, 2010:283–93 Metabolic Factors and Incident HFncident HF. Butler et al. (36) investigated the impact of
etabolic syndrome on cardiovascular outcomes in 3,031
ubjects age 70 to 79 years; metabolic syndrome was defined by
TP-III (Third Report of the National Cholesterol Educa-
ion Program Expert Panel on Detection, Evaluation, and
reatment of High Blood Cholesterol in Adults) criteria as any
of the following risk factors: increased waist circumference
men 101.6 cm and women 88.9 cm), high triglyceride
evel (150 mg/dl), low high-density lipoprotein (men40
g/dl, women 50 mg/dl), high blood pressure (130/
85 mm Hg), and high fasting glucose level (110 mg/dl).
etabolic syndrome was independently associated, not only
ith incident myocardial infarction and coronary events, but
lso with incident HF hospitalization (relative risk: 1.5, p
.009) in this cohort of older adults. However, when the
ubgroup of subjects without past history of coronary heart
isease or HF was analyzed, the relationship was no longer
tatistically significant (36). However, a study of 2,314
iddle-aged men without baseline HF or coronary heart
isease found metabolic syndrome, defined by ATP-III
riteria with BMI substituted for waist circumference, to be
significant, independent predictor of subsequent HF, even
fter adjusting for interim myocardial infarction (hazard
atio: 1.80, 95% CI: 1.11 to 2.91) (37).
HF risk may not be associated with the metabolic
yndrome per se, but rather with individual risk factors
eflected by metabolic syndrome. In the analysis of MESA
32), metabolic syndrome as defined by ATP-III criteria
Figure 3 Cumulative Incidence of Heart Failure According to C
Adapted with permission from Kenchaiah et al. (29).redicted a 2-fold increased risk of HF in unadjusted onalyses; however, after adjustment for known risk factors,
nly 2 specific components of the metabolic syndrome—
bdominal adiposity and high plasma glucose—were strong,
ndependent predictors of HF, whereas metabolic syndrome
tself was not. Li et al. (38), analyzing NHANES data,
ound the metabolic syndrome also to be associated with
-time higher risk of incident HF; in this analysis, insulin
esistance, as quantified by the homoeostasis model assess-
ent, accounted for 90% of the association between
etabolic syndrome and HF.
oes Risk Factor Modification Help Prevent HF?
t is clear from the multitude of epidemiologic data described
hat diabetes, insulin resistance, glucose, and obesity are risk
actors for the development of HF. Furthermore, it has been
hown that the absence of risk factors, or having “optimal risk
actors,” is associated with extremely low incidence of HF; the
ast majority of incident HF, close to 90%, is attributable to the
odifiable risk factors of diabetes, obesity, smoking, blood
ressure, and hypercholesterolemia (39). In light of the rapidly
ncreasing prevalence of obesity, diabetes, and pre-diabetes in
he U.S., it is imperative that HF prevention strategies include
odification of these risk factors.
iabetes. For patients with diabetes (type 1 or 2), the
merican College of Cardiology (ACC), American Heart
ssociation (AHA), and American Diabetes Association
ecommend glycemic control to HbA1c 7% for reduction
ries of Body Mass Indexategof cardiovascular risk (ACC/AHA Class IIb recommenda-
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Metabolic Factors and Incident HF January 26, 2010:283–93ion, Level of Evidence: A). These recommendations are
ased on long-term follow-up from the DCCT (Diabetes
ontrol and Complications Trial) and the UKPDS (UK
rospective Diabetes Study), which show a reduction in
ardiovascular risk at or around HbA1c of 7% (40).
However, more recent studies of more intensive glucose
ontrol have not yielded uniformly beneficial results. The
ADT (Glucose Control and Vascular Complications in
eterans with Type 2 Diabetes), including 1,791 patients
ith mean HbA1c at baseline of 9.4%, randomized
ubjects to intensive glucose control with metformin,
hiazolidinedione (TZD) (glitazone), and/or sulfonylurea
ersus usual care; although HbA1c was lower by a mean of
.5% at an average follow-up of 5.6 years in the intensive
herapy group, there was no significant difference in any
ardiovascular outcomes or all-cause mortality (41). The
DVANCE collaborative study group randomized 11,140
iabetic patients with mean HbA1c of 7.5% to intensive
lucose control defined as the use of gliclazide (modified
elease) plus other drugs as required to achieve a HbA1c
alue of 6.5% or less versus usual care; this study also
howed no significant effect on macrovascular events (42).
nother recent large, randomized, controlled clinical trial
ACCORD [Action to Control Cardiovascular Risk in
iabetes Study Group]), including 10,251 patients with
ype 2 diabetes and mean HbA1c of 8.1% at baseline,
ompared intensive treatment with a variety of oral and
nsulin-based medications and goal HbA1c 6% to usual
herapy; this trial was stopped early due to excess mortality
n the intensive treatment arm, although the primary com-
osite outcome of cardiovascular events was similar between
he 2 groups (43). And most recently, a meta-analysis
ncluding the above 3 trials plus UKPDS and PROactive
PROspective pioglitAzone Clinical Trial In macroVascular
vents) studied the effect of intensive control of glucose on
ardiovascular outcomes and death; this meta-analysis (44)
emonstrated an overall, significant reduction in nonfatal
yocardial infarction and coronary heart disease events with
ntensive treatment compared with standard treatment. The
verall effects of intensive glucose control on HF events and
ll cause mortality were neutral. However, there was signif-
cant heterogeneity between subgroups of studies separated
y glitazone use, suggesting that glitazone use was associ-
ted with excess risk of HF (44).
In light of strong association between diabetes, hypergly-
emia, and HF incidence, it is surprising that intensive
lucose control has not been more clearly linked with
ecreased HF incidence or improved cardiovascular out-
omes. There are several potential explanations for this lack
f benefit. It may be that only patients early in the course of
heir diabetes, rather than those with severe long-standing
isease, are able to reap the benefits of intense glucose
ontrol; only UKPDS, which included patients with a recent
iagnosis of diabetes, showed decreased risk of myocardial
nfarction with intensive glucose control (45). The excellent
ackground risk-reducing therapy in recent diabetes trials, 2ncluding over 86% of subjects in VADT and ACCORD on
tatins, may have made it more difficult to show incremental
isk reduction with glucose lowering (46). Furthermore,
ore frequent episodes of severe hypoglycemia were asso-
iated with more intensive glucose control in these clinical
tudies, and hypoglycemia may trigger adverse cardiovascu-
ar events (46). Another detrimental effect of intensive
lucose control seen in the majority of clinical trials was
ignificant weight gain (45).
One important reason for the surprising lack of effect of
ntense glucose control on HF incidence may be related to
edication choice. In patients with diabetes, the type of
ntidiabetic medication used in HF may impact the future
evelopment of HF. In a retrospective cohort study of 5,631
atients with new-onset diabetes started on oral mono-
herapy, sulfonylurea use was associated with significantly
igher risk of developing HF than metformin use; incidence
as 4.4 versus 3.3 per 1,000 persons, respectively, and
djusted hazard ratio was 1.24 (95% CI: 1.01 to 1.54) for
ulfonylurea compared with metformin (47). Another ob-
ervational study showed that diabetics treated with an
nsulin-containing regimen were at highest risk of HF,
hereas those treated with a metformin-containing regimen
ere at lowest risk (48). Of note, metformin compared with
ther antidiabetic therapies was also associated with de-
reased macrovascular risk in overweight diabetic subjects
tudied in the UKPDS (49). These data suggest that
etformin or perhaps other insulin-sensitizing regimens for
ubjects with diabetes may be preferable to those that
ncrease insulin levels, although prospective studies in this
rena are needed.
Glitazones, although insulin sensitizers, have been asso-
iated with edema and weight gain, and may increase the
isk of new-onset HF. A retrospective cohort study of type
diabetic patients identified by insurance claims (n 
3,544) found that TZD use was associated with a higher
djusted incidence of new-onset HF compared with no
ZD use (8.8% vs. 5.5% at 40 months) (50). The associa-
ion between TZDs and new-onset HF was confirmed in
nalyses of PROactive (51), which evaluated macrovascular
orbidity and mortality in subjects with cardiovascular or
eripheral vascular disease, but without baseline HF. Al-
hough subjects randomized to pioglitazone had a
onsignificant trend towards reduced mortality/vascular
vents in the primary analysis (51), higher rates of both
erious and nonserious HF were seen in the pioglitazone
roup (adjusted relative risk: 1.53 [95% CI: 1.18 to 1.98]).
mong those who developed HF, however, all-cause mor-
ality and HF deaths were similar between the 2 random-
zation groups, suggesting that perhaps TZDs are merely
ncreasing signs of HF in patients at risk (52). Echocardi-
graphy studies have shown no change in cardiac function
ith TZD therapy (53).
ifestyle modification and prevention. An essential com-
onent of HF prevention is reducing the incidence of type
diabetes. Lifestyle interventions, as definitively shown by
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January 26, 2010:283–93 Metabolic Factors and Incident HFhe Diabetes Prevention Program Research Group, can
ffectively reduce the incidence of type 2 diabetes. This
tudy randomized 3,234 subjects with overweight BMI
24 kg/m2) and impaired fasting glucose to standard
ifestyle recommendations plus placebo, standard lifestyle
ecommendations plus metformin, or an intensive program
f lifestyle modification including diet and exercise; result-
ng diabetes incidence rates were 11.0, 7.8, and 4.8 per 100
erson-years, respectively (p  0.0001). Reduction in inci-
ence of diabetes was highest for the lifestyle intervention
roup (58% risk reduction compared with the placebo group
nd 39% risk reduction compared with the metformin
roup) (54).
Medical therapy aimed at preventing the onset of diabetes
as been explored, but the success seen with lifestyle
nterventions has not been replicated. The DREAM (Dia-
etes REduction Assessment with ramipril and rosiglita-
one Medication) trial investigated whether medical therapy
ould prevent new-onset diabetes in patients with high
asting glucose levels or impaired glucose tolerance, but
ithout diabetes or cardiovascular disease; metabolic syn-
rome characteristics were common in this cohort, in which
ean waist circumference was 101 cm (men) and 96 cm
women) and mean blood pressure 135.9/83.3 mm Hg
55,56). Ramipril did not reduce the risk of new-onset
iabetes, rate of cardiovascular events, or new-onset HF in
his population (57). Rosiglitazone did prevent the onset of
iabetes in this high-risk group (relative risk: 0.38 [95% CI:
.33 to 0.44]). However, rosiglitazone did not alter the risk
f cardiovascular events and furthermore significantly in-
reased the risk of HF (7.04 [95% CI: 1.60 to 31.0]) (57).
hus, lifestyle modifications (diet and exercise) should be
ecommended as a primary intervention for those with
yperglycemia and/or metabolic syndrome who are at risk of
eveloping HF.
In light of clearly increased risk of HF with overweight
nd obesity, lifestyle interventions should be geared towards
ttaining a BMI 25 kg/m2. Diets aimed at weight loss,
ay not only reduce the incidence of overweight and
besity, but also reduce insulin resistance, diabetes, and the
etabolic syndrome (58,59). Reduced-calorie diets are ef-
ective at cardiovascular risk reduction regardless of the
acronutrient components of the diet, as shown in a recent
ietary intervention study of 811 overweight adults random-
zed to 1 of 4 diets with variable emphasis on protein, fat,
nd carbohydrate intake; diets resulted in similar weight
oss, decrease in waist circumference, lowered cholesterol
evels, as well as reduction in fasting insulin levels (59).
owever, prospective studies demonstrating that weight
oss results in lower risk of incident HF are needed.
revention of HF: What Is Established
atients at high risk of HF may be classified as having “Stage
” HF; Stage A patients are those without symptoms of HFnd without any structural heart disease who have risk factors
A
Lor HF such as diabetes, hypertension, obesity, or coronary
rtery disease (4). For those with Stage A disease, evidence-
ased, guideline-recommended interventions should be imple-
ented to decrease risk of HF (Table 2, Fig. 4).
An integral component of prevention in patients with
iabetes is systolic and diastolic blood pressure control, partic-
larly with angiotensin-converting enzyme inhibitors or angio-
ensin receptor blockers (60–62). The UKPDS study clearly
emonstrated that tight (150/85 mm Hg) compared with
ess tight (180/105 mm Hg) blood pressure control signifi-
antly reduces risk of HF; a 10-mm Hg decrease in systolic
lood pressure was associated with a 56% decreased risk of
ncident HF (63). Captopril and atenolol therapy were equally
fficacious in reducing risk of HF and other diabetes-related
omplications (64). A diabetes substudy (n  3,577) of the
OPE (Heart Outcomes Prevention Evaluation) also dem-
nstrated a 20% relative risk reduction in any HF events for
hose randomized to ramipril versus placebo (65).
In another subset of Stage A patients, those with coro-
ary artery disease, treatment of hypercholesterolemia with
tatin therapy is effective in reducing the risk of HF, as
hown in a substudy of the 4S (Scandinavian Simvastatin
urvival Study); new-onset HF was 10.3% in the placebo
roup compared with 8.3% in the simvastatin group (p 
.015) (66). Established medical therapies to reduce risk of
F in those at risk are outlined in Table 3.
aveat: Patients With Established HF
lthough obesity and dysglycemia are clear risk factors for
he development of HF, they are not risk factors for poor
rognosis in patients with chronic, established HF. In fact,
umerous studies have demonstrated a “reverse epidemiol-
gy” of obesity in HF; higher BMI has been associated with
mproved rather than impaired outcomes in chronic HF
28,67,68). Surprisingly, high compared with low HbA1c
as also been associated with better outcomes in 1 cohort of
atients with advanced systolic HF (69). Malnutrition,
achexia, and inflammation, all of which are associated with
evere HF and poor HF prognosis, may help explain these
lass I Recommendations for the Treatmentf Stage A HF From the ACC/AHA GuidelinesTable 2 Class I Recommendations for he Treatmentof Stage A HF From the ACC/AHA Guidelines
1. Treat systolic and diastolic hypertension according to guidelines
2. Treat diabetes according to guidelines
3. Treat atherosclerosis according to secondary prevention guidelines
4. Treat lipid disorders according guidelines
5. Encourage smoking cessation
6. Discourage heavy alcohol intake, illicit drug use
7. Periodic evaluations for signs and symptoms of HF
8. Noninvasive evaluation of LVEF in those with strong family history of
cardiomyopathy
9. Control of ventricular rate or restoration of sinus rhythm in those with
supraventricular tachycardia
10. Treat thyroid disorders according to contemporary guidelinesCC  American College of Cardiology; AHA  American Heart Association; HF  heart failure;
VEF  left ventricular ejection fraction.
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ased, guideline-recommended therapies for patients with
stablished HF (Stage C and D) are shown in Figure 4.
uture Directions
urther research is needed to understand the mechanisms
nvolved in progression from diabetes, obesity, and meta-
olic syndrome to incident HF and to identify additional
herapeutic targets for preventing HF. Prospective clinical
rials to establish optimal glycemic control targets for
educing the risk of incident HF are needed as well as
omparative effectiveness studies to determine which glyce-
ic control medications result in the lowest risk of new-
Figure 4 Recommended Therapies by Stage of HF Algorithm
Adapted with permission from Hunt et al. (60). Figure illustration by Rob Flewell. ACEI
EF  ejection fraction; FHx CM  family history of cardiomyopathy; HF  heart failurenset HF. Whether novel targets of therapy, such as Odipokines/resistin, inflammatory cytokines, or oxidative
arkers, may prove useful in preventing progression to HF
n high-risk patients needs further investigation. There is an
mportant need for research to better understand the con-
ribution of genetic factors to metabolic risk factors in the
isk of incident HF. There should also be pursuit of
harmacogenetic research to maximize the efficacy and
inimize the toxicity of medications for HF prevention.
Importantly, there is a need for further behavioral re-
earch on improving compliance and adherence to proven
herapies for managing HF risk factors. It is also essential
hat there be implementation of effective systems to ensure
se of evidence-based, guideline-recommended therapies
or prevention of HF in those with metabolic risk factors.
iotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker;
left ventricular; LVH  left ventricular hypertrophy; MI  myocardial infarction. ang
; LV f utmost importance is a greater awareness by both
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January 26, 2010:283–93 Metabolic Factors and Incident HFedical professionals and the public in the U.S. of: 1) the
ational and global impact of HF; 2) the importance of
iabetes, obesity, and metabolic syndrome as modifiable risk
actors for HF; and 3) evidence-based strategies that can
educe the incidence of HF. Initial studies in Europe have
hown a low level of awareness among the public as well as
low level of adherence to guideline-recommended thera-
ies by physicians; interventional educational programs are
eing undertaken (71–73).
onclusions
he emergence of HF as a global public health problem
ith high prevalence, high morbidity, and extraordinary
ost underscores the urgency of efforts to identify and
odify risk factors for incident HF. The vast majority of
ncident HF is due to preventable risk factors. Focus on the
rowing, inter-related epidemics of diabetes, obesity, and
etabolic syndrome is warranted, since it is established that
ifestyle interventions can decrease the risk of these syn-
edical Therapies to Reduce Risk of HFTable 3 Medical Therapies to Reduce Risk of HF
Clinical Trial
No.
Patien
Randomized, placebo-controlled trials
ACEI HOPE (ramipril, 2.5 or 10 mg) 9,2
ACEI EUROPA (perindopril, 8 mg) 12,2
ACEI SAVE (captopril, target 50 mg, TID) 2,2
Antiplatelet (ADP inhibitor) CURE (clopidogrel 300-mg load,
then 75 mg)
12,5
ARB RENAAL (losartan, 50 to 100 mg) 1,5
ARB IDNT (irbesartan, 300 mg) 1,7
Statin 4S (simvastatin 20 to 40 mg) 4,4
Randomized, active-controlled trials
Beta-blocker or ACEI,
with tight BP control
UKPDS (captopril or atenolol,
goal BP 150/85 mm Hg)
1,1
Retrospective studies
Beta-blocker SOLVD (subanalysis of prevention
trial)
2,1
Beta-blocker SAVE (subanalysis) 2,2
Including whites, blacks, and Hispanics. Adapted with permission from Schocken et al. (4).
4S  Scandinavian Simvastatin Survival Study; ACEI  angiontensin-converting enzyme inhibi
oronary artery disease; CURE  Clopidogrel in Unstable Angina to Prevent Recurrent Events trial;
table Coronary Artery Disease; HOPE Heart Outcomes Prevention Evaluation study; IDNT Irbe
ascular disease; RENAAL  Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist
ysfunction trial; TID  3 times per day; UKPDS  UK Prospective Diabetes Study; other abbreviaromes. Furthermore, appropriate medical treatment ofypertension, dyslipidemia, and hyperglycemia in those at
isk of HF is an essential component of prevention. Further
tudies are needed to better understand the inter-
elationship of these metabolic risk factors and incident HF
nd to develop more effective strategies to prevent HF in
hose at risk.
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